Structure

InChI Key JNTOCHDNEULJHD-UHFFFAOYSA-N
Smile Nc1nc(O)c2ncn(CCC(CO)CO)c2n1
InChI
InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H15N5O3
Molecular Weight 253.26
AlogP -0.9
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 5.0
Polar Surface Area 130.31
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 18.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human herpesvirus 1 DNA polymerase inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- 11000 - - 0

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Herpes Labialis 4 D006560 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Nervous system disorders Headache
Nervous system disorders Headache 39.3
Nervous system disorders Headache 22.7
Nervous system disorders Headache
Nervous system disorders Headache 13.5
Gastrointestinal disorders Nausea 12.5
Gastrointestinal disorders Nausea
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Nausea
Gastrointestinal disorders Diarrhoea 9.0
Nervous system disorders Headache 8.5
Gastrointestinal disorders Abdominal pain
Gastrointestinal disorders Abdominal pain 7.9
Gastrointestinal disorders Gastrointestinal pain
Gastrointestinal disorders Gastrointestinal pain 7.9
Gastrointestinal disorders Diarrhoea 7.7
Reproductive system and breast disorders Dysmenorrhoea 7.6
Gastrointestinal disorders Nausea 7.2
Nervous system disorders Headache
Reproductive system and breast disorders Dysmenorrhoea
Nervous system disorders Headache
Gastrointestinal disorders Diarrhoea 4.9
General disorders and administration site conditions Asthenia 4.8
Gastrointestinal disorders Diarrhoea
General disorders and administration site conditions Fatigue 4.8
Gastrointestinal disorders Flatulence 4.8
Gastrointestinal disorders Vomiting 4.8
General disorders and administration site conditions Asthenia 4.4
General disorders and administration site conditions Fatigue 4.4
Gastrointestinal disorders Nausea
Skin and subcutaneous tissue disorders Pruritus 3.7
Gastrointestinal disorders Nausea
Gastrointestinal disorders Abdominal pain
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Fatigue
Gastrointestinal disorders Gastrointestinal pain
Gastrointestinal disorders Vomiting
Skin and subcutaneous tissue disorders Dermatitis 3.3
Skin and subcutaneous tissue disorders Rash 3.3
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Fatigue
Blood and lymphatic system disorders Neutropenia 3.2
Nervous system disorders Migraine 3.1
Gastrointestinal disorders Vomiting 3.1
Skin and subcutaneous tissue disorders Pruritus
Nervous system disorders Paraesthesia 2.6
Gastrointestinal disorders Nausea 2.5
Gastrointestinal disorders Nausea 2.2
Skin and subcutaneous tissue disorders Pruritus 2.2
General disorders and administration site conditions Application site reaction
Reproductive system and breast disorders Dysmenorrhoea 1.8
General disorders and administration site conditions Asthenia 1.6
Skin and subcutaneous tissue disorders Dermatitis
Gastrointestinal disorders Diarrhoea 1.6
General disorders and administration site conditions Fatigue 1.6
Gastrointestinal disorders Flatulence
Skin and subcutaneous tissue disorders Rash
Gastrointestinal disorders Vomiting
Gastrointestinal disorders Flatulence 1.5
Blood and lymphatic system disorders Neutropenia
Nervous system disorders Hypoaesthesia
General disorders and administration site conditions Application site reaction 1.3
Blood and lymphatic system disorders Leukopenia 1.3
Gastrointestinal disorders Abdominal pain
Gastrointestinal disorders Diarrhoea
Gastrointestinal disorders Gastrointestinal pain
Gastrointestinal disorders Vomiting 1.2
Gastrointestinal disorders Abdominal pain 1.1
Gastrointestinal disorders Gastrointestinal pain 1.1
Nervous system disorders Hypoaesthesia 0.9
Blood and lymphatic system disorders Leukopenia
Nervous system disorders Paraesthesia 0.9
Gastrointestinal disorders Diarrhoea
Skin and subcutaneous tissue disorders Dermatitis
Reproductive system and breast disorders Dysmenorrhoea
Gastrointestinal disorders Flatulence
Nervous system disorders Migraine
Nervous system disorders Migraine 0.7
Skin and subcutaneous tissue disorders Rash
Gastrointestinal disorders Vomiting 0.7
General disorders and administration site conditions Asthenia 0.6
Reproductive system and breast disorders Dysmenorrhoea
General disorders and administration site conditions Fatigue 0.6
Gastrointestinal disorders Flatulence 0.6
Nervous system disorders Migraine
Nervous system disorders Migraine 0.6
Skin and subcutaneous tissue disorders Pruritus
Gastrointestinal disorders Vomiting
Gastrointestinal disorders Abdominal pain
General disorders and administration site conditions Asthenia
Skin and subcutaneous tissue disorders Dermatitis 0.4
Reproductive system and breast disorders Dysmenorrhoea
Reproductive system and breast disorders Dysmenorrhoea 0.4
General disorders and administration site conditions Fatigue
Gastrointestinal disorders Gastrointestinal pain
Skin and subcutaneous tissue disorders Rash 0.4
Gastrointestinal disorders Dysgeusia
Skin and subcutaneous tissue disorders Pruritus
Gastrointestinal disorders Abdominal pain 0.2
Gastrointestinal disorders Dysgeusia 0.2
Gastrointestinal disorders Flatulence 0.2
Gastrointestinal disorders Gastrointestinal pain 0.2
Nervous system disorders Migraine 0.2
Blood and lymphatic system disorders Anaemia 0.1
Skin and subcutaneous tissue disorders Dermatitis
Skin and subcutaneous tissue disorders Dermatitis 0.1
Immune system disorders Hypersensitivity
General disorders and administration site conditions Pain
Skin and subcutaneous tissue disorders Rash
Skin and subcutaneous tissue disorders Rash 0.1

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
33.88
Injury, poisoning and procedural complications
18.18
Skin and subcutaneous tissue disorders
14.88
Product issues
6.61
Nervous system disorders
5.79
Musculoskeletal and connective tissue disorders
4.96
Gastrointestinal disorders
4.13
Immune system disorders
3.31
Infections and infestations
3.31
Vascular disorders
2.48

Cross References

Resources Reference
CAS NUMBER 39809-25-1
ChEBI 7956
ChEMBL CHEMBL1540
DrugBank DB00299
DrugCentral 2079
EPA CompTox DTXSID9046491
FDA SRS 359HUE8FJC
Human Metabolome Database HMDB0014444
KEGG C07417
PDB PE2
PharmGKB PA450839
PubChem 135398748
SureChEMBL SCHEMBL3494
ZINC ZINC000000001899